Cellenkos, Inc. Announces FDA Registration of GMP Manufacturing Facility for Universal Donor Cell Therapeutics Derived from Cord Blood
HOUSTON, Feb. 6, 2018 — Cellenkos, Inc., a clinical-stage biotechnology company focused on developing universal donor cell therapeutics derived from cord blood (CB) for the treatment of autoimmune diseases and inflammatory conditions, today announced the successful registration of its stand-alone, manufacturing facility as GMP (good manufacturing practice) compliant with U.S. Food and Drug Administration (FDA). [Read more…]